According to the International Classification of Diseases - 10 (ICD-10), vision function is classified into four broad categories - normal vision, moderate vision impairment, severe vision impairment, and blindness. Visual impairment is a broad term, which involves moderate or severe vision loss or complete blindness. It is a global health concern that has a negative impact on both physical and mental health. Preventive blindness, which was considered among common ailments, will soon emerge as a major challenge to the global healthcare system. Blindness and visual impairment necessitate high costs as they not only constitute great productivity loss but also increase the burden on healthcare spending significantly. According to the International Agency for the Prevention of Blindness (IAPB), about 36 million people were categorized as blind, and about 217 million people were estimated to suffer from moderate to severe visual impairment (MVSI) in 2014. According to the World Health Organization (WHO), uncorrected errors, especially myopia, hyperopia, or astigmatism, constituted 43% of overall visual impairment cases in 2014.

The global infusion pumps and accessories market is primarily driven by rising incidence of the chronic diseases, such as cancer and others, coupled with the rising adoption of these devices, owing to broadening applications of infusion pumps. Currently, infusion pumps are widely used in the chemotherapy, diabetes management, and many other applications. The rising prevalence of these diseases, worldwide, is creating ample opportunities for market to grow. For instance, according to International Diabetes Federation (IDF), in 2019, there were approximately 463 people were living with diabetes and is estimated that the number is anticipated to grow to 700 million by 2045. In addition, technological advancements in the device technology, and companies' efforts in innovating products to meet the safety and increase the adoption of devices are likely to fuel the market growth. On the other hand, the market is being hindered by high cost of the infusion pumps, safety issues associated with the devices and infusion-related errors.

The report covers the detailed analysis of the trends, future estimations, and a thorough study of the global fish oil market on the basis of species and application. It analyzes government regulations, policies, and patents to provide information on the current market trends and suggests future growth opportunities globally. Furthermore, the study highlights Porter’s five forces analysis to determine the factors affecting the market growth. These factors include raw material prices, intense competition, end users, manufacturers, and suppliers. To understand the market, drivers, restraints, and opportunities are explained in the report. Furthermore, it includes the revenue generated from the sales of fish oil across North America, Europe, Asia- Pacific, and LAMEA.

Hemodialysis catheter is used for exchanging blood to and from hemodialysis device and a patient. The report provides market dynamics and trends related to the global chronic hemodialysis catheter market. In addition, it presents estimations and forecast of the market. The study estimates revenue generated from the sales of chronic hemodialysis catheters; however, it excludes chronic hemodialysis catheter service revenue. The valuations comprise revenue generated from chronic hemodialysis catheter type of tip such as step-tip catheter, split-tip catheter, and symmetric tip catheter. Furthermore, the report excludes revenue generated from postsale services of chronic hemodialysis catheter products.

Dental insurance is a type of contract that is represented by a policy and covers only the dental health or oral health of a person. Insurers have simplified their product offerings & made them straightforward with selective coverages and provide comparison of multiple dental treatments in terms of protection and premiums for selected coverages. Moreover, dental insurance reimburses several dental costs incurred by the patients and the insurers have been profiting from rise in number of individuals with high income, increased per capita earnings, and surge in working class population. For the purpose of analysis, the report of dental insurance market is segmented the basis of coverage, type, demographics, end user, and region. The highlights the various coverages available in the market, which include dental preferred provider organizations (DPPO), dental health maintenance organizations (DHMO), dental indemnity plans, and others. In addition, it covers various types of insurance offered, including major, basic, and preventive. Furthermore, it provides a detailed description on various demographics such as senior citizens, adults, and minors. The end users include individuals and corporates. An in-depth analysis across North America, Europe, Asia-Pacific, and LAMEA has been included in the study.

DNA methylation is a heritable epigenetic marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by enzymes known as DNA methyltransferases (DNMTs). In humans, DNA methylation occurs primarily at cytosines in any context of the genome. More than 98% of DNA methylation occurs in a CpG dinucleotide context in somatic cells. The current study aims to assess the global DNA methylation market by focusing on evaluating products catering to the aforementioned definition. The current scenario of DNA methylation detection and diagnosis is mainly dominated by several diagnostic majors, such as Illumina, Inc., Thermo Fisher Scientific Inc., Merck Group, and QIAGEN N.V., which offer a wide variety of products ranging from molecular-genetic tests to sequencing instruments for the confirmatory detection and diagnosis of DNA methylation. These products are generally based on technologies, such as polymerase chain reaction (PCR), microarrays, and sequencing, including both traditional and next-generation sequencing. The underlying utility of diagnostic testing for DNA methylation is based on the identification of clinically actionable genetic function, which provide crucial information on diagnosis, prognosis, and theranostics of genetic disorders and thereby facilitates clinical work-up, treatment management, and therapeutic selection.

Drug screening is used to identify prescription drugs and illicit drugs in urine, plasma, and other biological samples. Urine testing is the most commonly used sample type for drug screening. The report provides market dynamics and trends related to the global drug screening laboratory services market. In addition, it presents estimations and forecast of the drug screening services market majorly performed for various workplaces. The study estimates revenue generated from the services offered. The valuations comprise revenue generated from drug laboratory services. However, the report excludes revenues generated by counseling fees of doctors or healthcare providers who suggest various types of drug screening tests.

The global clinical nutrition market is expected to grow at a CAGR of 8.40% during the forecast period. Some of the major factors driving the growth of the clinical nutrition market include the growing geriatric population, increasing incidence of malnutrition among hospitalized patients and the growing prevalence of communicable and non-communicable chronic diseases such as diabetes and obesity. Further, the growing number of premature births and the rising demand for specialized infant formula are also driving the market growth.

The global cell & gene therapy market is one of the fastest-growing segments of the global regenerative medicine market. The market is growing at a healthy rate and this trend is expected to continue during the forecast period. This surge can be attributable to the growing prevalence of various chronic diseases like cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic diseases, and other rare diseases across the globe. For instance, the prevalence of cancer and diabetes is increasing among the global population, and the medical solutions through conventional treatment methods are limited. There is a large unmet need in the treatments available today, and this need is fulfilled by cell & gene therapies. The market is witnessing steady growth due to the increased availability of funding from various public and private institutes. In addition, there is increased support from the regulatory bodies for product approvals and providing fast-track designations to the products, which encourages vendors to manufacture the products at a faster rate. In addition, the government in various major nations is creating awareness about the cell & gene therapy among the population and bringing various strategies to facilitate affordability and payments for these treatments.

The report provides market dynamics and trends related to the global cancer vaccines market. In addition, it presents estimations and forecast of the market. The study estimates revenue generated from sales of cancer vaccines; however, it excludes cancer vaccines service revenue. Valuations comprise revenue generated from technologies such as dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. Furthermore, the report excludes revenue generated from post-sale services of cancer vaccines products.

医药三季报业绩前瞻，建议积极布局业绩增速快的子行业及公司。本周仅一个交易日，10 月9 日当天沪深300 上涨2.04%，医药生物行业上涨2.86%，处于28 个一级子行业第10 位。所有医药子板块均上涨，其中生物制品子板块涨幅最大，为4.29%，医药商业板块涨幅最小，为1.05%。三季报业绩亮眼、疫苗相关的个股涨势靠前，如凯普生物、智飞生物、华兰生物等。

妇科肿瘤药物在研临床项目中抗体类药物占比较多，以PD-L1/PD-1为主要靶点。在一线治疗研发药物中，李氏大药厂的ZKAB001 在治疗复发转移性宫颈癌的中国患者中显示出良好安全性及显著疗效，其ORR为22.6%，mPFS为5.4月；葛兰素史克的dostarlimab在dMMR型子宫内膜癌治疗中具有可接受的安全性，ORR为42.3%；先声药业的恩度联合以顺铂为基础的同步放化疗治疗局部进展期宫颈癌，其ORR可达100%，CR为48.3%。

鼻咽癌的药物研发以放化疗类药物为主，其中靶点众多，有EGFR、TYMS、Tubulin beta-1chain、放疗增敏剂等。

医药板块经历两个月明显调整，跌够了没有？从时间窗口上看，8、9月医药板块较大幅度连续下跌，2017年以后除了2018年下半年首次带量采购带来的影响外，很少有连续两个月大幅下跌；从调整空间上看，近两个月医药指数下跌约12%，也是2017年以后除了首次带量采购外较为少见的情况；从估值上看，尽管医药板块PE（TTM）近49倍，相对于均值36倍仍较高，主要是百年不遇的疫情影响导致医药板块结构化较贵，主流医药板块2021年估值已经比较合理；从板块表现看，十一前机构重仓股明显调整，很可能为医药板块最后一跌。

8 月国内合计批签发血制品763.67 万瓶，同比下降19.49%；1-8 月国内累计批签发血制品6800.36 万瓶，同比增长23.49%。

本周回顾与周专题：本周申万医药指数上涨2.86%，位列全行业第10，跑赢沪深300 指数，跑输创业板指数。本周周专题，我们呈现了全球疫情最新进展与全球疫苗、中和抗体研发进展总结。

sum近m期ar，y＃我 们对重点覆盖的 59 家医药上市公司 2020Q3 业绩进行了预测，预计2020 年Q3 净利润增速超过50%的有12 家；净利润增速30%-50%的有13 家；净利润增速20%-30%的有9 家；净利润增速0-20%的有21家；净利润同比下滑的公司有1 家。

本周上证综指上涨1.64%，报3272.08 点，中小板上涨4.41%,报8936.37 点，创业板上涨5.22%，报2672.93点。医药生物同比上涨2.53%，报11871.21 点，表现强于上证0.89 个pp，弱于中小板1.88 个pp，弱于创业板2.69 个pp。全部A 股估值为15.64 倍，医药生物估值为50.62 倍，对全部A 股溢价率为223.59%，处于历史较高水平。

上半年实现收入106.91亿美元，同比-2.51%。新冠疫情主要影响肝炎和心血管的在售药品，但6月份已经开始好转，公司全年收入指引中低个位数增长不变，预计能实现收入230-250亿美元。

海外疫情形势严峻，疫苗是控制新冠疫情的最佳手段。疫情爆发以来，新冠病毒疫苗研发以前所未有的速度在进行，根据WHO统计，截至10月2日全球有超过190种候选疫苗正在研发，其中42种已经进入临床试验阶段, 10种疫苗进入Ⅲ期临床。我国的多种疫苗研发处于国际第一方阵，其中国药中生灭活疫苗（武汉所和北京所两款）、康希诺/军科院腺病毒载体疫苗、科兴中维灭活疫苗进入Ⅲ期临床，与海外合作研发的腺病毒载体疫苗（康泰/阿斯利康/牛津大学）、mRNA疫苗（复星/辉瑞/BioNTech）亦进入Ⅲ期临床。